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Introduction: In lung cancer, interleukin-22 (IL-22) expression 
within primary tissue has been demonstrated, but the frequency 
and the functional consequence of IL-22 signaling have not been 
addressed. This study aims at analyzing the cellular effects of IL-22 
on lung carcinoma cell lines and the prognostic impact of IL-22 tis-
sue expression in lung cancer patients.
Methods: Biological effects of IL-22 signaling were investigated in 
seven lung cancer cell lines by Western blot, flow cytometry, real-
time polymerase chain reaction, and proliferation assays. Tumor 
tissue specimens of two cohorts with a total of 2300 lung cancer 
patients were tested for IL-22 expression by immunohistochemistry. 
IL-22 serum concentrations were analyzed in 103 additional patients 
by enzyme-linked immunosorbent assay.
Results: We found the IL-22 receptor 1 (IL-22-R1) to be expressed 
in six of seven lung cancer cell lines. However IL-22 signaling was 
functional in only four cell lines, where IL-22 induced signal trans-
ducer activator of transcription 3 phosphorylation and increased cell 
proliferation. Furthermore, IL-22 induced the expression of anti-
apoptotic B-cell lymphoma 2, but did not rescue tumor cells from 
carboplatin-induced apoptosis. Cisplatin-resistant cell lines showed a 
significant up-regulation of IL-22-R1 along with a stronger prolifera-
tive response to IL-22 stimulation. IL-22 was preferentially expressed 
in small- and large-cell lung carcinoma (58% and 46% of cases, 
respectively). However, no correlation between IL-22 expression by 
immunohistochemistry and prognosis was observed.
Conclusion: IL-22 is frequently expressed in lung cancer tissue. 
Enhanced IL-22-R1 expression and signaling in chemotherapy-
refractory cell lines are indicative of a protumorigenic function of 
IL-22 and may contribute to a more aggressive phenotype.
Key Words: Lung cancer, Small-cell lung cancer, Large-cell lung 
cancer, Interleukin-22, Interleukin-22-receptor 1.
(J Thorac Oncol. 2013;8: 1032-1042)
Interleukin-22 (IL-22) is a unique cytokine of the IL-10 family acting exclusively on interleukin-22-receptor 1 (IL-22-R1) 
positive epithelial cells.1 IL-22 induces antimicrobial proteins 
such as defensins in epithelial cells, protects against damage, 
and promotes regeneration in injured tissues.2 These functions, 
including up-regulation of antiapoptotic pathways and 
increased proliferation, are protective in acute inflammatory 
conditions and in tissue injury,3,4 but may be deleterious in 
chronic states where proliferation or antiapoptosis promote 
disease, as demonstrated in psoriasis.5 Several signal 
transducers downstream of the IL-22-R1 have been described, 
including signal transducer activator of transcription (STAT)1 
STAT5, extracellular-signal-regulated kinases (ERK), c-Jun 
N-terminal kinases (JNK), and p38.6 In cancer cells, however, 
the main signaling pathway downstream of the IL-22-R1 is 
STAT3, which mediates most IL-22–induced effects.2,7,8 In 
the lung, IL-22 has been found to be expressed by alveolar 
epithelial cells, macrophages, and T cells.9,10 Both exogenous 
IL-22 and IL-22 produced by immune cells protect lung tissue 
from acute injury induced by ventilation trauma or viral 
infection.3,11 Thus, the lung is an organ in which epithelial 
cells can react to IL-22 and resident cell populations are 
capable of producing IL-22. Interestingly, many cancer cell 
lines, including those of lung origin, express the IL-22-R1.12 
Recent work by Zhang et al.7 suggests that IL-22 is an 
autocrine mediator in non–small-cell lung cancer (NSCLC). 
In the current study, we analyzed 2300 lung cancer samples 
for IL-22 expression by immunohistochemistry and also 
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studied IL-22 serum levels in lung cancer patients. Further, 
we investigated IL-22-R1 expression, signal transduction, and 
proliferative response to IL-22 in lung cancer cell lines.
PATIENTS AND METHODS
Patients and Patient-Derived Samples
Two tissue microarrays (TMAs) were established from 
a total of 203 (TMA1) and 2097 (TMA2) lung cancer speci-
mens of archived tissue samples at the Institute of Pathology 
at the University Medical Center Hamburg-Eppendorf, the 
University Hospital Freiburg, and the Kantonspital Basel (col-
lected between 1994 and 2006), respectively. All tissues were 
obtained from patients who were undergoing lobectomy or 
pneumectomy. Tissue samples were formalin-fixed (buffered 
neutral aqueous 4% solution), paraffin-embedded, and used for 
TMA construction, as previously described.13 Hematoxylin-
eosin–stained sections were used to define representative 
tumor regions. Tissue cylinders (0.6 mm in diameter) were 
then punched from that region of the block with the use of a 
self-developed semiautomated tissue arrayer.14 Survival data 
were available for 1724 patients. The mean follow-up period 
was 29.1 months (range, 3–200 months). Survival data were 
either obtained from the cancer registry, or collected from the 
patients’ attending physicians. All tissues included in these 
TMAs had been reviewed by an expert pathologist determin-
ing histological type and histological grade. The pathologically 
determined tumor stage (pT), nodal (pN), and metastasis (pM) 
status were obtained from the primary reports of the depart-
ment of pathology. The collection and TMA-based screenings 
of human tumor samples were in compliance with the ethi-
cal principles for medical research established by the World 
Medical Association’s Declaration of Helsinki in its current 
version. An overview of the patient cohort is given in Table 1.
Serum samples from 103 patients with early-stage lung 
cancer were obtained from the Asklepios Biobank of Lung 
Diseases. All patients gave their informed consent.
Serum samples from age- and sex-matched healthy 
donors (n = 70) were provided by the Bavarian Red Cross 
(Blutspendedienst des Bayerischen Roten Kreuzes gemein-
nützige GmbH).
Cell Lines
Lung cancer cell lines H187, H1339, LOU-NH91, 
HCC827, and A549 were purchased from the German 
Collection of Microorganisms and Cell Cultures (Deutsche 
Sammlung von Mikroorganismen und Zellkultur (DSMZ), 
Braunschweig, Germany). The cisplatin-resistant cell lines 
H1339-R and HCC827-R have been described.15 De novo 
cisplatin-resistant cell lines HCC827-R2 and A549-R were 
generated, as previously described.15
Scratch Assay
Scratch assay was performed, as described.16 Cells were 
stimulated for 4 hours in 1% fetal calf serum (FCS) medium 
(Dulbecco’s Modified Eagle Medium (DMEM) or Roswell 
Park Memorial Institute (RPMI) supplemented with 1% pen-
icillin-streptomycin [PS] of 10,000 U/ml and 10,000 µg/ml 
stock solution; respectively) and 1% L-glutamine (of 200 mm 
stock solution) with or without IL-22 (Peprotech, Hamburg, 
Germany) or gardiquimod (InvivoGen, Toulouse, France) at 
the indicated concentrations. Cell-free area was measured and 
calculated using Image J software (freeware established by R. 
Stallmann and available for download under http://rsbweb.nih.
gov/ij/download.html). Mitomycin C was used at 10 µg/ml.
Western Blot
Western blot was performed, as previously described.17 
Antibodies used included polyclonal antibody against IL-22-R1 
(Sigma, St. Louis, MO), monoclonal antibody against pSTAT3 
(Tyr705, clone B-7; Santa Cruz, Heidelberg, Germany), 
monoclonal antibody against STAT3 (clone F-2; Santa Cruz), 
polyclonal antibody against BCL-2 (N19, sc492; Santa 
TABLE 1.  Clinical and Pathologic Characteristics of 2097 
Patients (TMA2)a
Characteristics
Study Cohort on TMA 
No. of Patients
Histology
 Squamous cell carcinoma 980 (47%)
 Adenocarcinoma 569 (27%)
 Bronchioalveolar carcinoma 92 (4%)
 Large-cell carcinoma 379 (18%)
 Small-cell carcinoma 63 (3%)
 Adenosquamous carcinoma 14 (1%)
Follow-up
Overall survival (mo)
 Median 23.0
 Mean 35.2
Sex
 Male 1265 (77%)
 Female 377 (23%)
Age (yr)
 ≤60 702 (40%)
 >60 1070 (60%)
 Mean age (yr) 63 (11–92)
pT category
 pT1 453 (22%)
 pT2 1167 (56%)
 pT3 300 (14%)
 pT4 154 (7%)
pN category
 pN0 1027 (51%)
 pN1 489 (24%)
 pN2 442 (22%)
 pN3 58 (3%)
pM category
 pM0 1958 (93.8%)
 pM1 130 (6.2%)
aNumbers do not add up to 2097 in the different categories because of cases with 
lack of data.
pT, pathologically determined tumor stage; pN, pathological nodal; pM, pathological 
metastasis; TMA, two tissue microarray.
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Cruz), monoclonal antibody against β-actin (clone C4; Santa 
Cruz), polyclonal antibody against mouse immunoglobulin 
(IgG), horseradish peroxidase (HRP)-labeled (Cell Signaling, 
Frankfurt, Germany), and polyclonal antibody against rabbit 
IgG, HRP-labeled (Santa Cruz).
Enzyme-Linked Immunosorbent Assay
Enzyme-Linked immunosorbent assay for IL-22 detec-
tion was obtained from Research & Development, (R & D) 
Abington, United Kingdom. Absorption was then measured 
at 450 nm using a Mithras LB940 multilabel plate reader 
(Berthold Technologies, Bad Wildbad, Germany).
Real-Time Polymerase Chain Reaction
Quantitative RT-PCR was performed as previously 
described.17 The following primers were designed using the 
online Roche assay design center: IL-22-R1-fwd: 5′-TTA 
TTT TTC CAT TGT CTC TGT CCA -3′, IL-22-R1-rev: 5′- 
TGG CAG CAC ATT TCC TTG TAA CT – 3′, HPRT-fwd: 
5′ - CGA GCA AGA CGT TCA GTC CT - 3′, and HPRT-rev: 
5′ - TGA CCT TGA TTT ATT TTG CAT ACC–3′, together 
with the probes 28 and 73 of the Roche Universal Probe 
Library (Roche, Mannheim, Germany). Primer efficiency 
was determined experimentally by serial dilutions of cDNA 
at 2.13 for the IL-22-R1 primer pair and at 1.95 for the HPRT 
pair. Expression of IL-22-R1 relative to HPRT was calculated 
using the light cycler relative quantification software based 
on the formula: relative expression = NT × ETCpT/NR × 
ERCpR where NT is the number of target molecules at detec-
tion threshold Cp, NR is the number of reference molecules 
at detection threshold Cp, ET is the efficiency of target ampli-
fication, and ER is the efficiency of reference amplification.
Vitality and Proliferation Assay
For assessing cell vitality, cell titer blue assay was performed 
in accordance with the protocol of the manufacturer (Promega, 
Mannheim, Germany). Stimulation by or neutralization of IL-22 
was performed in serum-free medium (DMEM or RPMI, 1% PS 
and 1% L-Glutamine). Positive controls for vitality or proliferation 
were assessed in culture medium supplemented as above includ-
ing, in addition, 10% FCS. For IL-22 neutralization, polyclonal 
antibody against IL-22-R (R & D) and monoclonal antibody 
against IL-22 (clone 142928; R & D) were added to the culture. 
For STAT3 inhibition, the specific inhibitor STATTIC (Sigma, 
Taufkirchen, Germany) was used at a concentration of 25 µM.
Apoptosis Assay by Annexin 
V-Propidium Iodide Staining
Cells were treated either with carboplatin (Ratiopharm, 
Ulm, Germany) at the indicated concentrations: STATTIC (10 
µM) or IL-22 (100 ng/ml) for 48 hours in supplemented culture 
medium (DMEM or RPMI with 10% FCS, 1% PS and 1% 
L-Glutamine). Afterward, cells were stained with propidium 
iodide nucleic acid stain (Invitrogen, Paisley, United Kingdom) 
and annexin V allophycocyanin (APC)-conjugated antibody 
(ImmunoTools, Friesoythe, Germany). Cells were studied by 
flow cytometry using a FACS Canto II (Becton Dickinson, 
Heidelberg, Germany), and data were analyzed with Flow Jo 
software (Version 7.6.5; Tree Star Inc., Ashland, Oregon).
IL-22 Immunohistochemistry
Freshly cut 3-μm thick TMA sections were analyzed 
on 1 day in a single experiment. IL-22 expression was 
detected with a polyclonal rabbit antibody (ab18944; abcam) 
in a dilution of 1:150 after peroxidase blocking with H
2
O
2
 
(DAKO S2023; DAKO, Hamburg, Germany) for 10 min-
utes. Slides were pretreated at high-temperature in an auto-
clave (121°C) with citrate buffer, pH 6 for 5 minutes. The 
Envision system (DAKO 5007) was used to visualize immu-
nostaining. The IL-22 antibody was pretested on a separate 
TMA containing biopsies of normal tissue (colon; n = 3; 
endometrium, n = 4, lung, n = 4, epididymidis, n = 2) as nega-
tive controls (no IL-22 expression) and biopsies with malig-
nant tissue (colon cancer; n = 10), where IL-22 expression has 
been previously described (positive control)18.
For each tissue spot, IL-22 staining was scored by cyto-
splasmatic staining intensity (0, 1+, 2+, or 3+) and by esti-
mation of the fraction of positive tumor cells. A composite 
score was built from these two parameters according to the 
following scheme: Low expression was defined as a staining 
intensity of 0 and 1+ in less than 70% of tumor cells or a stain-
ing intensity of 2+ in less than 30% of tumor cells. Positive 
expression was defined as a staining intensity of 1+ in more 
than 70% of tumor cells, a staining intensity of 2+ in more 
than 30% of tumor cells, or a staining intensity of 3+.
Statistical Analyses
For statistics JMP 7.0 software (SAS institute Inc., Cary, 
NC) or GraphPad Prism Software, version 5.0b (GraphPad 
Software, LaJolla, CA) were used. All Student’s t tests were 
two-sided and p values less than 0.05 were considered sig-
nificant. Differences between experimental conditions were 
analyzed using the unpaired Student’s t test. Regression analy-
sis was used to compare variances. To study the relationship 
between IL-22 expression and clinical–pathological param-
eters, contingency table analysis and χ2 test (likelihood) was 
used. Overall survival was analyzed by the Kaplan–Meier 
method and was compared using log-rank test.
RESULTS
Lung Cancer Cell Lines Express IL-22-R1 but 
React Heterogeneously to IL-22 Stimulation
Seven lung cancer cell lines were studied for the biological 
effects of IL-22 signaling: A549, HCC827, H1339, H187, 
LOU-NH91, HCC827-R, and H1339-R (the latter 2 cisplatin-
resistant). Six of seven cell lines (85%) were found positive for 
IL-22-R1 expression by Western blot and RT-PCR (Fig. 1A and 
data not shown). None of the cell lines were found to express 
IL-22 (data not shown). To test for IL-22-R1 functionality, cell 
lines were stimulated with recombinant IL-22, and subsequent 
STAT3 phosphorylation was analyzed by Western blot (Fig. 
1B). Four of the six cell lines (66%) expressing IL-22-R1 
showed IL-22-induced STAT3 phosphorylation (see Fig. 1B, 
C for A549 and HCC827-R, data not shown for H1339-R 
1035Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 8, Number 8, August 2013 IL-22 is Expressed in Small and Large Cell Lung Cancer
Ka
rpa
s29
9
A5
49 HC
C8
27
HC
C8
27-
R
H1
339 H1
339
-R
H1
87
PB
MC
Interleukin-22-R1
Beta-Actin
A
B
D
Un
stim
.
10 
min
.
30 
min
.
60 
min
.
p-STAT3
STAT3
Beta-Actin
p-STAT3
STAT3
Beta-Actin
Un
stim
.
IL-
22 
+ 
a-
IL-
22 
+ 
a-
IL-
22-
R 
p-STAT3
STAT3
Beta-Actin
Un
stim
.
IL-
22 
30 
min
.
IL-
22 
60 
min
.
Un
stim
. +S
TAT
TIC
30 
min
 + 
STA
TT
IC
60 
min
 + 
STA
TT
IC
Un
stim
.
30 
min
.
60 
min
.
p-STAT3
STAT3
Beta-Actin
Un
stim
.
30 
min
.
60 
min
.
A549 HCC827-R HCC827
LO
U-N
H9
1
A549 A549
0 30 60
0
2
4
6
8
Time [min]
No
rm
a
liz
e
d 
to
 
pS
TA
T3
 
u
n
st
im
u
la
te
d
n=5
n=5
n=5
ns
A549
0 30 60
0
2
4
6
8
Time [min]
No
rm
a
liz
e
d 
to
 
pS
TA
T3
 
u
n
st
im
u
la
te
d HCC8227R
n=4
n=4
n=4
nsC
FIGURE 1.  IL-22-R1–positive lung carcinoma cell lines react to IL-22 in a specific manner. A, Expression analysis of IL-22-R1 
in the lung cancer cell lines A549, HCC827, HCC827-R, H1339, H1339-R, H187, and LOU-NH91 by Western blot. The cell 
line Karpas 299 and human PBMC served as positive and negative controls, respectively. β-actin served as loading control. B, 
Detection of STAT3 phosphorylation on IL-22 stimulation in the cell lines A549, HCC827-R and HCC827. Lysates were made 
10, 30, and 60 minutes after stimulation. STAT3 and β-actin served as loading controls. C, Densitometric analysis of pSTAT3 of 
five, respectively four independent stimulations of cell lines A549 and HCC827R with IL-22 (100 ng/ml) for 30 and 60 minutes. 
D, Stimulation of cell line A549 with IL-22 in the presence or absence of IL-22 or IL-22-R1 blocking antibodies. IL-22–induced 
STAT3 phosphorylation was detected after 30 minutes of stimulation with IL-22. A549 was also stimulated with IL-22 in the 
presence or absence of the specific STAT3 inhibitor STATTIC (25 µM). STAT3 phosphorylation is shown after 30 and 60 minutes, 
respectively. For all Western blots, the results of one of three representative experiments are shown. PBMC, peripheral blood 
mononuclear cells; IL-22, interleukin-22. 
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FIGURE 2 Continued
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and H187). The cell lines H1339, LOU-NH91, and HCC827 
did not respond by STAT3 phosphorylation (see Fig. 1B 
for HCC827, data not shown for H1339 and LOU-NH91). 
Specificity of the signaling was demonstrated using IL-22 
neutralizing and IL-22-R1 blocking antibodies and a specific 
STAT3 phosphorylation inhibitor (Fig. 1D).
IL-22 Induces Proliferation in IL-22 
Responsive Lung Cancer Cell Lines
Lung cancer cell lines that are reactive to IL-22 as evi-
denced by STAT3 phosphorylation were tested for IL-22–
induced proliferation. IL-22 stimulation resulted in an increase 
in proliferation as compared with unstimulated cells (Fig. 2A). 
The observed effect was dependent on IL-22 signaling through 
STAT3 because IL-22–blocking antibodies and STAT3 inhibi-
tion completely suppressed IL-22–induced cell proliferation 
(Fig. 2B). Subsequently, we investigated the impact of IL-22 
on re-epithelialization in a standardized scratch assay. IL-22 
induced faster re-epithelialization of the scratch as compared 
with the unstimulated control (Fig. 2C). Because IL-22 stimu-
lation showed no dose dependency between 100 and 50 ng/ml 
in proliferation assays, we chose to test the effect of IL-22 in 
scratch assay using 100 ng/ml and 10 ng/ml (Fig. 2C). A trend 
toward a dose dependency was observed. Again, the faster re-
epithelialization was only observed in IL-22-sensitive cell lines 
(Fig. 2D). Suppression of IL-22-mediated re-epithelialization 
by mitomycin C treatment, which blocks proliferation but not 
migration, indicates that replenishment of the scratch area is 
mediated predominantly by tumor cell proliferation (Fig. 2D).
IL-22 Does Not Protect Lung Cancer Cell Lines 
from Chemotherapy-Induced Apoptosis
IL-22 has been described to protect epithelial cells from 
apoptosis through up-regulation of antiapoptotic proteins such 
as BCL-2.19 We used the chemotherapeutic drug carboplatin, 
which induces apoptosis in cancer cells by cross-linking of 
DNA strands. Treatment with IL-22 had no impact on cell via-
bility or on the rate of apoptosis in carboplatin-exposed A549 or 
HCC827-R cells (Fig. 3A, B). Similar observations were made 
for the chemotherapeutic drug 5-FU (Supplementary Figure 
1A, Supplemental Digital Content 1, http://links.lww.com/JTO/
A434). IL-22 induced a weak BCL-2 up-regulation in these 
cell lines (Fig. 3C). Gardiquimod served as a positive control 
for Bcl-2 induction (Supplementary Figure 1C, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A434).20
Chemotherapy-Resistant Cell Lines Up-
regulate IL-22-R1 Expression and Signaling
Because resistance to standard chemotherapeutic agents 
such as cisplatin is a common event in lung cancer treatment, 
we attempted to determine whether drug-resistant cells have an 
altered response to IL-22. Cell lines A549 and HCC827 were 
repeatedly exposed to cisplatin, which resulted in resistance 
to both cisplatin and cisplatin-induced apoptosis (Fig. 4A and 
Supplementary Figure 1B, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A434). These cell lines were des-
ignated A549-R and HCC827-R2, respectively. Interestingly, 
A549-R and HCC827-R2 up-regulated IL-22-R1 expression as 
assessed by RT-PCR and Western blot (Fig. 4B). Up-regulation 
of IL-22-R1 expression correlated with a stronger IL-22-induced 
proliferative response as compared with passage-matched non-
resistant controls (Fig. 4C). These data indicate that cisplatin-
resistant cell lines are more sensitive to IL-22 signaling and this 
may contribute to the aggressive phenotype of these cells.
IL-22 Is Preferentially Expressed in Primary 
Large- and Small-Cell Lung Cancer
To further investigate how the above-described in vitro 
effects impact on human lung cancer disease, we first tested 
whether IL-22 is expressed in primary lung cancer tissue, by 
staining 203 samples from patients with NSCLC and small-
cell lung cancer (SCLC) (TMA1; Table 2) for IL-22 expres-
sion. IL-22 was expressed in all histological subtypes with 
the highest positive proportion in SCLC (85%; Fig. 5A, B). 
Adenocarcinoma (ADCA), bronchoalveolar carcinoma, and 
large-cell carcinoma exhibited similar expression rates with 
54%, 45%, and 44%, respectively. Morphologically, the tumor 
tissue, that is, the cancer cells themselves mainly stained posi-
tive for IL-22 expression. Squamous cell carcinoma (SQCC) 
showed the least frequent expression of IL-22 (23%). To con-
firm these findings, we next analyzed a second cohort con-
taining 2097 samples from patients with NSCLC (n = 2034; 
97%) or SCLC (n = 63; 3%) for IL-22 expression (Table 3). 
Of 2097 TMA tissue spots stained for IL-22 expression, 1815 
spots (86%) were evaluable for IL-22 expression analysis. 
FIGURE 2. Continued  IL-22 induces STAT3-mediated cell proliferation in lung carcinoma cell lines. A, Cell proliferation measure-
ment by cell titer blue assay on IL-22 (either 50 or 100 ng/ml as indicated) stimulation for the cell lines A549, HCC827-R, and 
HCC827. Ten percent serum served as positive control and serum-free medium as baseline control. Values were normalized to the 
mean value of unstimulated controls. The results of one of three representative experiments are shown. The error bars repre-
sent the standard error of the mean of the replicates (n = 6). B, Cell proliferation measurement by cell titer blue assay on IL-22 
stimulation (100 ng/ml) for the cell line A549 in the presence or absence of IL-22 or IL-22-R1 blocking antibodies or STATTIC. 
Values were normalized to the mean value of unstimulated controls. The results of one of three representative experiments are 
shown. The error bars represent the standard of mean of the replicates (n = 3). C, Light microscopy image of representative 
scratches applied to cell line A549 in the presence or absence of IL-22. Results are shown for the time points 0, 24, and 36 hours. 
The results of one of three representative experiments are shown. D, Measurement of cell-free surface in a scratch assay in the 
presence or absence of IL-22 (10 ng/ml or 100 ng/ml, respectively) for the cell lines A549, HCC827-R, and HCC827. Extent of 
re-epithelialization was normalized to the unstimulated controls. The cell line A549 was treated, in addition, with mitomycin C in 
the presence of IL-22. The results of one of three representative experiments are shown. Error bars represent the standard error 
of the mean of the replicates (n = 12). For all experiments, *indicates a p value less than 0.05, **indicates a p value less than 0.01, 
and ***indicates a p value less than 0.001, and a nonsignificant difference. IL-22, interleukin-22; ns, nonsignificant.
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The remaining 282 samples were noninformative because of 
absence of tissue on the TMA or a lack of unequivocal tumor 
cells in the arrayed samples. Expression of IL-22 was again 
found in a majority of SCLC samples (58%; Fig. 1C). Large-
cell carcinoma had the second highest proportion of IL-22 
expression (46%; Fig. 1C), whereas, ADCA, bronchoalveo-
lar carcinoma, and SQCC expressed IL-22 only in smaller 
proportions of samples (33%, 24%, and 28%, respectively). 
Contingency table analysis confirmed a higher expression in 
SCLC and large-cell carcinoma compared with the other his-
tological subtypes (p < 0.0001; Table 3). Expression of IL-22 
by large-cell carcinoma is supported by the analysis of serum 
IL-22 levels in a small cohort (n = 103) of patients undergo-
ing surgery for ADCA, SQCC, or large-cell carcinoma. Two 
of the three patients in this cohort with large-cell lung carci-
noma had higher IL-22 concentrations in their serum (998 and 
964 pg/ml) compared with matched healthy controls (mean 53 
pg/ml), with ADCA (mean 28 pg/ml), or with SQCC (mean 
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88 pg/ml) patients (Supplementary Figure 1A, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A434). Because 
of this differential expression of IL-22 among different lung 
cancer subtypes, we investigated a possible correlation of 
IL-22 expression with clinical–pathological parameters.
IL-22 Expression Does Not Correlate with 
Prognosis in Resected NSCLC and SCLC
We first tested the patient cohort of TMA2 for known 
prognostic parameters such as pathologically determined 
pT, pN, and pM. Advanced T stage (pT3 or pT4), positive 
nodal status (pN1–3), and pM1 all correlated significantly 
with reduced overall survival (p < 0.0001 for all compari-
sons, Supplementary Figure 2A, Supplemental Digital 
Content 2, http://links.lww.com/JTO/A435). Having 
established that the studied cohort is representative for 
standard prognostic factors, we analyzed the influence of 
IL-22 expression on prognosis in the complete cohort (Fig. 
5D) and in the different histological subtypes separately 
(Supplementary Figure 2B, Supplemental Digital Content 
2, http://links.lww.com/JTO/A435). IL-22 did not corre-
late with prognosis in any of the groups analyzed (Fig. 5D; 
Supplementary Figure 2B, Supplemental Digital Content 2, 
http://links.lww.com/JTO/A435). Moreover, we found no 
significant difference in IL-22 expression between differ-
ent tumor stages (Table 3).
DISCUSSION
So far, a single study has reported IL-22 to be expressed 
in a small cohort of lung carcinoma samples.7 The significance 
of this finding for the patients remained unclear. Our current 
study is the first to address the frequency of expression and the 
prognostic value of IL-22 expression in lung cancer. Analyzing 
two independent patient cohorts, we found SCLC and large-
cell carcinoma to predominantly express IL-22 among all sub-
types analyzed. In IL-22-responsive cell lines (4 of 7), IL-22 
induced STAT3-mediated proliferation but not migration or 
protection from chemotherapy-induced apoptosis. We found 
TABLE 2.  Correlation of IL-22 Expression with Pathologic 
Characteristics of TMA1
Histology IL-22 High (%) IL-22 Low (%)
Adenocarcinoma 30 (45) 36 (55)
Bronchioalveolar 
carcinoma
18 (24) 56 (76)
Large-cell carcinoma 20 (44) 24 (56)
Small-cell carcinoma 11 (85)  v2 (15)
Squamous cell carcinoma 13 (23) 44 (77)
Unknown  6 (60)  4 (40)
TMA, two-tissue microarray.
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de novo–generated cisplatin-resistant cell lines to up-regulate 
IL-22-R1 and have a stronger proliferative response to IL-22 
stimulation, indicating a possible role of IL-22 when a relapse 
after chemotherapy has occurred. However, in the large clini-
cal cohort, IL-22 expression did not correlate with survival 
time in any of the histological subtypes.
Our data are in agreement with the data of Zhang et 
al.,7 who have shown IL-22 expression in lung cancer samples 
both by immunohistochemistry and RT-PCR. Our data con-
firm the finding by Zhang et al. and other groups that lung 
cancer cells are responsive to IL-22.3,9 Importantly, expression 
of IL-22-R1 has been found to be up-regulated in lung cancer 
samples.21 However, because all lung cancer cell lines were 
found negative for IL-22 protein expression, expression of 
IL-22 in primary tissue may arise from nontumor cells or from 
the interaction between tumor and nontumor cells and stroma. 
The frequent expression we have found in large-cell lung cor-
relates with the elevated serum concentrations we have found 
in large-cell lung cancer patients. No elevated serum concen-
trations were found in patients with the IL-22 low-express-
ing ADCA or SQCC. In contrast to the findings of Zhang et 
al.,7 who suggested a chemotherapy-protective role of IL-22 
through Bcl-2 up-regulation, IL-22 had no impact on chemo-
therapy-induced apoptosis in the current study, irrespective 
of the mechanism of apoptosis induction (adduct formation 
with DNA for carboplatin or blockade of thymidine synthesis 
by 5-fluorouracil), despite a slight Bcl-2 up-regulation. This 
discrepancy may be explained by the only modest impact on 
apoptosis described in the previous study.
The impact of cisplatin resistance on the expression of 
the IL-22-R1 may reflect a response to cell stress induced by 
chemotherapy. Although the exact mechanism and the regu-
lation of this receptor remains unaddressed, up-regulation of 
IL-22-R1 has been reported to be induced by proinflammatory 
cytokines such as interferon-α and tumor necrosis factor-α.22,23 
The up-regulation of IL-22-R1 in a setting of acute stress may 
contribute to a rescue of these cells, if IL-22 is present.23
Not surprisingly, none of the analyzed tumor cell lines 
secreted notable levels of IL-22, congruent with previous 
reports.7 This discrepancy versus the positive IL-22 expres-
sion in primary tumor tissue may be because of differences 
in expression between cell lines and primary tumors observed 
in other contexts.24 However, because IL-22 expression has 
not been demonstrated in healthy epithelial cells, the source 
of IL-22 in the tumor environment may be the infiltrating 
immune cells. In fact, tumor infiltrating IL-22–positive T cells 
have been demonstrated in lung cancer, hepatocellular car-
cinoma, and gastric cancer.25–27 Other potentially IL-22 pro-
ducing cells (e.g., Th17-cells) have been detected in several 
cancer types, including lung cancer.28 In addition, IL-22 can 
be produced by NK and myeloid cells, also found in the tumor 
microenvironment.29,30
It is surprising that despite IL-22 expression in a sub-
stantial number of the tumors, we were unable to find a cor-
relation with prognosis, as has been suggested for IL-22 in 
gastric and hepatocellular carcinoma.26,27 According to our 
data, there may be several explanations for this discrepancy: 
First, we have found lung cancer cell lines to respond hetero-
geneously to IL-22, which, if representative of the patients’ 
situation, may indicate that not every cancer will respond to 
IL-22. Second, the impact of IL-22 on proliferation only and 
not on apoptosis may be insufficient to overcome the thera-
peutic effect of the operation performed in these patients. 
Third, IL-22-R1 expression may vary among tumor cells and 
because the receptor is a prerequisite for IL-22 reaction, IL-22 
expression would need to be compared with IL-22-R1 expres-
sion, which according to our data directly impacts on IL-22 
response. However, no loss or down-regulation of IL-22-R1 
in cancer patients has been demonstrated so far. Most reports 
analyzing IL-22-R1 in lung cancer or other tumor types agree 
that IL-22-R1 is strongly expressed within all cancer tissues 
analyzed.7,21,27 Accordingly, a receptor-based lack of effect 
of IL-22 may only be because of mutations in the coreceptor 
IL-10R2 or to downstream signaling defects, such as activat-
ing STAT3 mutations.31,32 Because most patients will receive 
chemotherapy at some point during the course of their disease, 
it seems possible, based on our observation, that chemother-
apy-resistant cells are more prone to IL-22 stimulation. In this 
case tumor tissue IL-22 expression prognostic at a later time 
TABLE 3.  Correlation of IL-22 Expression with the Clinical 
and Pathologic Characteristics of TMA2a (n = 1815)
Characteristics
IL-22 
High (%)
IL-22  
Low (%) p
Histology >0.0001
 Adenocarcinoma 146 (29) 363 (71)
 Bronchioalveolar carcinoma 7 (54) 6 (46)
 Large-cell carcinoma 141 (47) 162 (53)
 Small-cell carcinoma 29 (58) 21 (42)
 Squamous cell carcinoma 283 (34) 553 (66)
Sex 0.44
 Male 400 (37) 693 (63)
 Female 112 (34) 215 (66)
Age (yr) 0.49
 ≤60 207 (14) 385 (26)
 >60 333 (22) 574 (38)
pT category 0.12
 pT1 124 (36) 219 (64)
 pT2 355 (36) 641 (64)
 pT3 94 (36) 167 (64)
 pT4 32 (25) 94 (75)
pN category 0.18
 pN0 314 (37) 540 (63)
 pN1 136 (32) 293 (68)
 pN2 131 (34) 256 (66)
 pN3 22 (43) 29 (57)
pM category 0.81
 pM0 571 (35) 1063 (65)
 pM1 34 (36) 60 (64)
aNumbers do not add up to 1815 in the different categories because of cases with 
lack of data.
pT, pathologically determined tumor stage; pN, pathological nodal; pM, pathological 
metastasis.
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point in the disease course not covered by the tissue samples 
studied here. In conclusion, we found no evidence for IL-22 
as a prognostic biomarker in early, potentially curable lung 
cancer. Further studies are needed to address the impact of 
IL-22 in advanced lung cancer, especially in SCLC and large-
cell lung cancer.
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